Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Oil Prices Slide as OPEC, IEA Cut 2026 Demand Forecasts
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales
Australia Housing Crisis Deepens as Worker Shortages Delay Homebuilding
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan
U.S. Stock Futures Flat Ahead of July CPI Data
SpaceX Shares Surge as Wall Street Backs AI Growth Potential
US Judge Dismisses Gautam Adani Criminal Charges
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow
Oil Prices Rise as Hormuz Tensions Threaten Global Supply
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes
Hanwha Offers Up to $1.2 Billion for Austal US Business
Gold Price Holds Near $4,400 as Hormuz Risks and CPI Drive Markets
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight
ASX Faces Legal Action Over Failed Blockchain CHESS Project
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 



